Seeking Alpha

World Market Pulse's  Instablog

World Market Pulse
Send Message
An unbiased, neutral, multi-anglular, practical & sharp view on all world markets & key tradeable assets including currencies, Exchange traded funds ETFs, Stocks equities and Futures, all commodities, with a world market perspective, focusing on key financial markets, offering timely and... More
My company:
Free newletter from world market pulse
My blog:
World market Pulse
  • Understanding Spherix Inc. Movement And Statistical Significant Results  0 comments
    Oct 8, 2010 9:38 AM | about stocks: SPEX, BIOS
    Spherix Incorporated (NASDAQ:SPEX) witnessed a real roller coaster ride after D-tagatose, a product originally developed as a reduced-calorie sugar substitute, hit statistical significance in a Phase III trial in Type II diabetes, as the company's stocks slumped 12% to $1.20 after rising as much as 55.50% earlier in the morning session. If all the market movement was not good enough, the company also announced that it has agreed to sell $5.25 million of shares of its series B convertible preferred stock and warrants to purchase shares of its common stock in a registered offering to institutional investors. The company plans to use the net proceeds from the offering to continue the development of D-tagatose for diabetes and triglycerides, as well as for general corporate purposes.

    Although most traders are wary of giving any undue reliance on any forward-looking statements based on statistical parameters that speak only as of the date of the release, the announcement has indeed triggered an interest in the company from all quarters for both medium as well as the long term.

    The company, which reported promising initial data from the drug Naturlose last November, said the drug was more effective in the U.S. population than in the Indian population. Type 2 diabetes occurs when the body loses its ability to use insulin to convert food to fuel.  Spherix meanwhile intends to submit a detailed analysis of the Phase 3 data to a peer-reviewed medical journal after the complete study report is received later this year.  Spherix will also post the final trial results on the public NIH ClinicalTrials.gov website as required by law. Spherix Incorporated (Spherix) operates in two segments: Biospherics and Health Sciences. Biospherics is the Company’s biotechnology research and development business.


    Global Pharmaceutical Sales 2011:


    According to an annual forecast by IMS Health, global pharmaceutical sales are expected to increase by 5 to 7 percent to as much as $890 billion in 2011, while the China market is seen growing at a torrid pace.

    The U.S. however is likely to remain by far the world's largest market, with sales forecast to reach $320 billion to $330 billion in 2011. But that represents growth of just 3 to 5 percent. The top five European markets of Germany, France, Italy, Spain and Britain will collectively grow at an even more anemic pace of 1 to 3 percent to $135 billion to $145 billion, as government pricing pressures limit growth.


    Disclosure: No Positions
Back To World Market Pulse's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • There is a breakout and a good long setup for DGWIY.PK a chinese water company Could be a good buy at 27.07
    Mar 31, 2010
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.